Alligator Bioscience has Reached a Successful Milestone

Alligator Bioscience AB has announced the achievement of key success milestone in its collaboration with Bayer HealthCare AG.

In this collaboration, first announced in October 2005, Alligator has succeeded to improve the expression level from undetectable to above the goal for the project, using Alligator's proprietary ssDNA recombination technology, FIND.

According to the agreement Alligator Bioscience will receive up-front and milestone payments for the development as well as milestone payments during the clinical development of the final product.

Alligator Bioscience uses its proprietary FIND technology to develop new and optimize existing therapeutic and diagnostic proteins.

Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers' proteins and helping them to build more competitive pipelines. The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development.

For further information please contact:

Gun-Britt Fransson,

CEO

Tel. +46 46 286 42 84

Email: guf@alligatorbioscience.com

Or visit www.alligatorbioscience.com